Evidence map›Paper›PMID 39552712›Full record

ArticleBiochemistry and biophysics reports2024

LINC00261 triggers DNA damage via the miR-23a-3p/CELF2 axis to mitigate the malignant characteristics of

Qingyuan Tao, Xiaojin Li, Yanyan Xia, Bin Zheng, Yijun Yan, Songrun Wang, Li Jia

Abstract read
In one paragraph

Article in Biochemistry and biophysics reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qingyuan TaoThe Affiliated Hospital of Yunnan University (Yunnan Second People's Hospital), Nuclear Medicine, Kunming, Yunnan, 650021, China.
Xiaojin LiThe Affiliated Hospital of Yunnan University (Yunnan Second People's Hospital), Central Laboratory, Kunming, Yunnan, 650021, China.
Yanyan XiaThe Affiliated Hospital of Yunnan University (Yunnan Second People's Hospital), Nuclear Medicine, Kunming, Yunnan, 650021, China.
Bin ZhengThe Affiliated Hospital of Yunnan University (Yunnan Second People's Hospital), Nuclear Medicine, Kunming, Yunnan, 650021, China.
Yijun YanThe Affiliated Hospital of Yunnan University (Yunnan Second People's Hospital), Nuclear Medicine, Kunming, Yunnan, 650021, China.
Songrun WangThe Affiliated Hospital of Yunnan University (Yunnan Second People's Hospital), Nuclear Medicine, Kunming, Yunnan, 650021, China.
Li JiaThe Affiliated Hospital of Yunnan University (Yunnan Second People's Hospital), Nuclear Medicine, Kunming, Yunnan, 650021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-chain non-coding RNA (LINC00261) in the treatment of papillary thyroid carcinoma (PTC) with Methods: The database and RT-qPCR were used to analyze the expression level of LINC00261 in PTC and cell lines. PTC cells resistant to Results: PTC cell lines exhibited a decrease in the expression of LINC00261. The growth and progression through the S-phase of TPC-1/R cells were suppressed by LINC00261, leading to increased apoptosis and DNA damage. The objective of LINC00261 was to regulate the axis of miR-23a-3p/CELF2. Downregulating LINC00261 enhances the growth and advancement of Conclusions: LINC00261 activates DNA damage in

Indexed as

131I-resistant papillary thyroid carcinoma cellsCELF2DNA damageLINC00261miR-23a-3p

Identifiers

PMID39552712
PMCPMC11564912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.